Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sanofi (SNY) Interest Expenses (2016 - 2026)

Sanofi's Interest Expenses history spans 16 years, with the latest figure at -$208.4 million for Q1 2026.

  • On a quarterly basis, Interest Expenses rose 6.99% to -$208.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$1.7 billion, a 14.6% increase, with the full-year FY2025 number at $655.4 million, down 42.84% from a year prior.
  • Interest Expenses hit -$208.4 million in Q1 2026 for Sanofi, up from -$655.4 million in the prior quarter.
  • Over the last five years, Interest Expenses for SNY hit a ceiling of -$98.8 million in Q1 2022 and a floor of -$1.4 billion in Q4 2023.
  • Historically, Interest Expenses has averaged -$388.2 million across 5 years, with a median of -$224.1 million in 2025.
  • Biggest five-year swings in Interest Expenses: plummeted 821.34% in 2023 and later surged 53.7% in 2025.
  • Tracing SNY's Interest Expenses over 5 years: stood at -$151.0 million in 2022, then plummeted by 821.34% to -$1.4 billion in 2023, then increased by 17.58% to -$1.1 billion in 2024, then skyrocketed by 42.84% to -$655.4 million in 2025, then soared by 68.2% to -$208.4 million in 2026.
  • Business Quant data shows Interest Expenses for SNY at -$208.4 million in Q1 2026, -$655.4 million in Q4 2025, and -$687.4 million in Q3 2025.